All-stock transactions will give Quanome approximately 5% stake in QAI Labs, the developer of NOVA-3, an AI-enabled platform designed for multi-specific antibody discovery New York, Nov. 09, 2026 (GLOBE NEWSWIRE) --
First Cash Milestone Payment Under 60-Month Enterprise Order Supports Procurement and Build-Out of Dedicated AI Computing Capacity NEW YORK, NY, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Quanome Technologies, Inc.
Initial 60-Month Order Has a Total Commitment Value Exceeding $100 Million; Service-Start Conditions Apply New York, NY, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Quanome Technologies, Inc. (NASDAQ:QNME) ("Quanome"
Insider Scaled Capital Support Reflects Confidencein Quanome's Strategic Direction and Future Potential NEW YORK, NY, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Quanome Technologies, Inc. (NASDAQ:QNME) ("Quanome"
Company Advances Development of First U.S. AI Infrastructure Hub, Executes Its Quantum & AI Systems Strategy ITASCA, Ill., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Quanome Technologies, Inc. (NASDAQ:QNME)
International expert platforms bring together scientific expertise across four quantum streams to advance understanding, collaboration and real-world application ITASCA, Ill., Aug. 20, 2026 (GLOBE NEWSWIRE) --
Common Stock Begins Trading on the Nasdaq Capital Market Under "QNME" ITASCA, Ill., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Quanome Technologies, Inc. (formerly Lakeside Holding Limited) (NASDAQ:QNME,
